- Home
- BCSF vs ZYME Comparison
BCSF vs ZYME Comparison
Compare BCSF & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- ZYME
- Stock Information
- Founded
- BCSF 2015
- ZYME 2003
- Country
- BCSF United States
- ZYME United States
- Employees
- BCSF N/A
- ZYME N/A
- Industry
- BCSF Finance/Investors Services
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- ZYME Health Care
- Exchange
- BCSF Nasdaq
- ZYME Nasdaq
- Market Cap
- BCSF 1.1B
- ZYME 973.9M
- IPO Year
- BCSF 2018
- ZYME 2017
- Fundamental
- Price
- BCSF $17.28
- ZYME $13.62
- Analyst Decision
- BCSF Hold
- ZYME Buy
- Analyst Count
- BCSF 4
- ZYME 6
- Target Price
- BCSF $16.75
- ZYME $19.17
- AVG Volume (30 Days)
- BCSF 194.9K
- ZYME 581.7K
- Earning Date
- BCSF 02-25-2025
- ZYME 03-05-2025
- Dividend Yield
- BCSF 10.40%
- ZYME N/A
- EPS Growth
- BCSF N/A
- ZYME N/A
- EPS
- BCSF 1.99
- ZYME N/A
- Revenue
- BCSF $294,257,000.00
- ZYME $62,199,000.00
- Revenue This Year
- BCSF N/A
- ZYME $21.53
- Revenue Next Year
- BCSF N/A
- ZYME N/A
- P/E Ratio
- BCSF $8.70
- ZYME N/A
- Revenue Growth
- BCSF 3.17
- ZYME N/A
- 52 Week Low
- BCSF $14.78
- ZYME $7.97
- 52 Week High
- BCSF $17.97
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- BCSF 51.57
- ZYME 45.35
- Support Level
- BCSF $16.79
- ZYME $12.80
- Resistance Level
- BCSF $17.80
- ZYME $17.07
- Average True Range (ATR)
- BCSF 0.28
- ZYME 0.84
- MACD
- BCSF -0.06
- ZYME -0.07
- Stochastic Oscillator
- BCSF 41.53
- ZYME 19.20
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.